drugset / Trial / NCT00832052

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

NCT00832052

Phase 1 Completed 32 enrolled Pfizer
RandomizedParallel-groupDouble-blind

Summary

Evaluate the safety and tolerability of PF-04447943 after administration of multiple doses in healthy elderly participants. Evaluate plasma drug levels and effects on cognition.

Timeline

Start
2009-01
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject EDELINONTRINE Small molecule 5 mg Oral
Subject EDELINONTRINE Small molecule 15 mg Oral
Subject EDELINONTRINE Small molecule 35 mg Oral

Indications

No indication recorded.